Press Release
<< Back
Verastem to Present Scientific Results at the 2013 AACR Annual Meeting
The research presented is in support of multiple current and upcoming
clinical trials.
The schedule for the
Date & Time:
Poster
Title: FAK inhibition preferentially attenuates growth of
Merlin-negative malignant mesotheliomas: role of cancer stem cells
Abstract
Number: 924
Session ID: Experimental and Molecular
Therapeutics 3
Location: Hall A-C, Poster Section 38
Date & Time:
Poster
Title: The dual PI3K/mTOR inhibitor VS-5584 preferentially targets
cancer stem cells in vitro and in vivo
Abstract
Number: 239
Session ID: Tumor Biology 2
Location:
Hall A-C, Poster Section 13
Date & Time:
Poster
Title: Pharmacological and genetic inhibition of FAK attenuates
cancer stem cell function in vitro and in vivo
Abstract
Number: 236
Session ID: Tumor Biology 2
Location:
Hall A-C, Poster Section 13
Date & Time:
Poster
Title: Cancer stem cell-selected patient-derived xenograft models
with sensitivity to FAK and Pan-PI3K/mTOR inhibitors
Abstract
Number: 221
Session ID: Tumor Biology 2
Location:
Hall A-C, Poster Section 13
About
Forward-looking statements:
This press release includes
forward-looking statements about the Company’s strategy, future plans
and prospects, including statements regarding the development of the
Company’s compounds, including VS-6063, VS-4718 and VS-5584, and the
Company’s FAK, PI3K/mTOR and diagnostic programs generally, the timeline
for clinical development and regulatory approval of the Company’s
compounds, the structure of the Company’s planned clinical trials and
estimates of the Company’s ability to fund operations. The words
“anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds may
not be predictive of the success of later clinical trials, that the
Company will be unable to successfully complete the clinical development
of its compounds, including VS-6063, VS-4718 and VS-5584, that the
development of the Company’s compounds will take longer or cost more
than planned, and that the Company’s compounds will not receive
regulatory approval or become commercially successful products. Other
risks and uncertainties include those identified under the heading “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Investors:
Brian Sullivan,
617-252-9314
bsullivan@verastem.com
or
Media:
Kari
Watson, 781-235-3060
kwatson@macbiocom.com